GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: glucagon stopped being a problem at week 32 — 45 comments in the full submission. View in context.
1.5k
c/retatrutide·submitted 1 months ago by u/nadia_norgaard

small win: glucagon stopped being a problem at week 32

Trial Databranch of 6 comments

Six-word version is the title — small win: glucagon stopped being a problem at week 32 — and the rest is context. Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding. The fatigue profile felt…

Read the full submission and all 45 comments →

This branch

6 comments, started 1 months ago
u/kavya_kravchenko230 points·1 months ago

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

replysharereportpermalink
u/nadia_trevino0 points·1 months ago

a lot of the confident posting here is extrapolation

replysharereportpermalink
u/kofi_balogun1 point·1 months ago

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide1 point·1 months ago

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

replysharereportpermalink
u/soren_nkemelu1 point·1 months ago

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

replysharereportpermalink
u/crosspost_bot_no0 points·1 months ago

a lot of the confident posting here is extrapolation

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/retatrutide
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/reta_and_regretu/trialwatch_theou/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →